TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05349344

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic circuit training
Description: Aerobic Exercise Training, 3 times a week for 8 weeks, (Tuesday, Thursday \& Saturday, 24 sessions Total) 30 min each time, at 60-80 % of HR max (moderate intensity).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Outdoor walk
Description: 30minutes Walking outside below 40% of HR max for 2 months.(3 times per week for 8 weeks).
Study: NCT03602118

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenobarbital Sodium Injection
Description: Phenobarbitone Inj, Phenobarbitone SOD, Phenobarbitone Sodium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenobarbital Sodium Injection
Description: Phenobarbitone Inj, Phenobarbitone SOD, Phenobarbitone Sodium
Study: NCT02496624

Intervention type: OTHER
Group type: OTHER
Intervention: Cone Beam CT localization and placement of microcoil
Description: Cone Beam CT localization and placement of microcoil
Study: NCT02975973

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: transcranial direct current stimulation (tDCS) is a safe, noninvasive, weak electrical current delivery that stimulates brain function. It is a novel therapeutic for cognition in schizophrenia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: transcranial direct current stimulation (tDCS) is a safe, noninvasive, weak electrical current delivery that stimulates brain function. It is a novel therapeutic for cognition in schizophrenia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: transcranial direct current stimulation (tDCS) is a safe, noninvasive, weak electrical current delivery that stimulates brain function. It is a novel therapeutic for cognition in schizophrenia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: transcranial direct current stimulation (tDCS) is a safe, noninvasive, weak electrical current delivery that stimulates brain function. It is a novel therapeutic for cognition in schizophrenia.
Study: NCT03923348

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leva device
Description: The leva® Pelvic Digital Health System by Renovia Inc is a novel tool for subjects with urinary incontinence to train and strengthen pelvic floor muscles via directional mechano-transductive feedback on performance in the privacy of their own homes.
Study: NCT00067015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin acetate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: assessment of therapy complications

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: assessment of therapy complications

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT03232970

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full Plate Diet
Description: 12 weekly sessions on how to incorporate more fiber in the diet.
Study: NCT02429765

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACL/FOR

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00538135

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Standard National Health Service treatment as usual for borderline personality disorder

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Standard National Health Service treatment as usual for borderline personality disorder
Study: NCT01273454

Intervention type: DRUG
Intervention: OROS Hydromorphone
Description: 8,16, 32 mg once a day for 4 weeks
Study: NCT02369094

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupressure
Description: A 15 minutes structured acupressure protocol with specific acupoints and applications technique will be performed on the elderly participants twice a week by the research team in YCHSS centers. The caregiver of the elderly will be trained and perform the same acupressure protocol on the elderly at 2 additional occasions during the week. The total trial period is 12 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: acupressure
Description: A 15 minutes structured acupressure protocol with specific acupoints and applications technique will be performed on the elderly participants twice a week by the research team in YCHSS centers. The caregiver of the elderly will be trained and perform the same acupressure protocol on the elderly at 2 additional occasions during the week. The total trial period is 12 weeks.
Study: NCT02264704

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity exericse
Description: Participants will exercise at high intensity (70% VO2 peak) intermittently (30 seconds on, 30 seconds off) for 15 minutes, twice weekly for 15 weeks. Workload may increase as the study progresses based on heart rate response.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate intensity exericse
Description: Participants exercise at moderate intensity (35% VO2 peak) continuously for 15 minutes, twice weekly for 15 weeks. Workload may increase as the study progresses based on heart rate response.
Study: NCT03605095

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitroglycerin
Description: Vasodilatator solution is dropped on the gingiva.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitroglycerin
Description: Vasodilatator solution is dropped on the gingiva.
Study: NCT01603264

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05280014
Description: Concentrate for solution for infusion, sterile vial 150 mg, single-dose 6 mg/kg administered as 90-minute infusion on day 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin
Description: Concentrate for solution for infusion, sterile vial 150 mg, single-dose 6 mg/kg administered as 90-minute infusion on day 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin
Description: Concentrate for solution for infusion, sterile vial 440 mg, single-dose 6 mg/kg administered as 90-minute infusion on day 1
Study: NCT01311960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab eye drop 0.05%
Description: bevacizumab eye drop 0.05% will apply 4 times a day for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: normal saline 0.9%
Description: normal saline eye drop 0.9% will apply 4 times a day for 3 months.
Study: NCT02610348

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines
Description: Original Vaccine in Study A3L12 (NCT00401531). No vaccination will be administered as part of this study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-HB-IPV and Pneumococcal polysaccharide vaccines
Description: Original Vaccine in Study A3L12 (NCT00401531). No vaccination will be administered as part of this study
Study: NCT04330638

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Usual Care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra
Description: Anakinra will be given as a daily subcutaneous injection of 100 mg for 28 days or until hospital discharge, whichever is first

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra
Description: Anakinra will be given as a daily subcutaneous injection of 100 mg for 28 days or until hospital discharge, whichever is first
Study: NCT03512210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Velpatasvir (SOF/VEL)
Description: 400/100 mg fixed-dose combination (FDC) tablet administered orally once daily with or without food.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Minimal Monitoring (MINMON) Strategy
Description: MINMON Strategy:~1. No pre-treatment HCV genotyping~2. Entire treatment course (84) tablets of SOF/VEL administered to participants at study entry~3. No scheduled on-treatment laboratory monitoring or clinic visits~4. Remote contact with participants at week 4 and week 22
Study: NCT01266291

Intervention type: DRUG
Group type: OTHER
Intervention: vigabatrin
Description: Subjects will begin taking vigabatrin (Sabril) during the third month of the study. Upward titration will happen at a rate of 500mg per week until subjects reach their maximum tolerated dose, or 3g per day (whichever is lower). This dose may be decreased if needed under the supervision of the study doctor. Subjects who need to lower their dose or who stop taking Sabril will have their dosage decreased at a rate of 1 gm/week for one month under the supervision of the study doctor.
Study: NCT04330638

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra
Description: Anakinra will be given as a daily subcutaneous injection of 100 mg for 28 days or until hospital discharge, whichever is first

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Siltuximab
Description: Siltuximab will be given via single IV infusion at a dose of 11 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Siltuximab
Description: Siltuximab will be given via single IV infusion at a dose of 11 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Tocilizumab will be given via single IV infusion at a dose of 8 mg/kg with a maximum infusion of 800 mg/injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Tocilizumab will be given via single IV infusion at a dose of 8 mg/kg with a maximum infusion of 800 mg/injection
Study: NCT01596582

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Assessment
Description: Patients randomized to the experimental arm will be asked a complete the ACNI risk assessment tool after reviewing a web-based colorectal cancer decision aid. The ACNI uses a point based system to stratify patients into low (mean rate of ACN \~3%) versus intermediate/high (\~ 8%) risk groups based on responses to 6 items: age (50-59, 60-69, 70+), sex (male/female), race/ethnicity (non-Hispanic black, other), smoking history (never, \<20 years, 20+ years), daily alcohol intake (\< 2 vs. \>/=2 drinks) and use of non-steroidal anti-inflammatory drugs (ever, never). The index represents a prototype version of the Advanced Colorectal Neoplasia Index (Am J Gastroenterol 2015;110:1062-71).
Study: NCT04879550

Intervention type: DIAGNOSTIC_TEST
Intervention: Antithrombin III
Description: Antithrombin III deficiency causes thrombosis. Is thrombosis in ECMO patients related to Antithrombin III deficiency? Groups with and without thrombosis will be separated and whether it is related to Antithrombin III deficiency will be evaluated.
Study: NCT02211326

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing algorithm for warfarin
Description: Intervention：initial dosing of warfarin for the first 3 days of treatment will be determined by IWPC( International Warfarin Pharmacogenetics Consortium) algorithm (PG-1),a second dose adjustment will be made after 3 doses of warfarin using a dose revision algorithm (PG-2) that combined INR values,the dose will be adjusted depending on the measurements of INR values after 7 days.The overall follow-up period is 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard initiation dose for warfarin
Description: Intervention：initial dosing of warfarin for the first 3 days of treatment will be determined by standard initiation dose. Following this initiation dose of warfarin,the dose will be adjusted depending on the measurements of INR values after 3 days.The overall follow-up period is 12 weeks.
Study: NCT01274195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: First dose: busulfan (120 mg/m2 ivs once daily) (if age\<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
Study: NCT02679261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Oral administration atorvastatin 20 mg per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration placebo
Study: NCT01417299

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: RPh201
Description: Patients will receive 400 microliter s.c., of RPh201 twice a week for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Patients will receive 400 microliter s.c., of saline twice a week for 3 months
Study: NCT01978613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0113-0987
Description: Tablets for once-daily oral administration. Multiple doses with sequential dose increments over 10 weeks. The end-dose levels and the dose levels during the escalation regime may be adapted during trial conduct based on safety evaluations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0113-0987
Description: Tablets for once-daily oral administration. Multiple doses with sequential dose increments over 10 weeks. The end-dose levels and the dose levels during the escalation regime may be adapted during trial conduct based on safety evaluations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0113-0987
Description: Tablets for once-daily oral administration. Multiple doses with sequential dose increments over 10 weeks. The end-dose levels and the dose levels during the escalation regime may be adapted during trial conduct based on safety evaluations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0113-0987
Description: Tablets for once-daily oral administration. Multiple doses with sequential dose increments over 10 weeks. The end-dose levels and the dose levels during the escalation regime may be adapted during trial conduct based on safety evaluations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0113-0987
Description: Tablets for once-daily oral administration. Multiple doses with sequential dose increments over 10 weeks. The end-dose levels and the dose levels during the escalation regime may be adapted during trial conduct based on safety evaluations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Tablets for one-daily oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Tablets for one-daily oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Tablets for one-daily oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Tablets for one-daily oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Tablets for one-daily oral administration.
Study: NCT02106299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Regen sling
Description: Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a Regen sling (medprin).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tension-free vaginal tape-obturator(TVT-O)
Description: Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator sling TVT-O™ (gynecare™, USA).
Study: NCT03327987

Intervention type: BIOLOGICAL
Intervention: standard of care influenza vaccine
Description: The standard of care annual 2017-2018 influenza vaccine will be used for this study.
Study: NCT03887676

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arbaclofen
Description: Administered orally as disintegrating tabs, round, white and beveled edges, at the following strengths: 5mg, 10mg, 15mg and 20mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally as disintegrating tabs, round, white and beveled edges
Study: NCT03327987

Intervention type: BIOLOGICAL
Intervention: standard of care influenza vaccine
Description: The standard of care annual 2017-2018 influenza vaccine will be used for this study.

Intervention type: BIOLOGICAL
Intervention: standard of care influenza vaccine
Description: The standard of care annual 2017-2018 influenza vaccine will be used for this study.
Study: NCT00554970

Intervention type: DRUG
Group type: OTHER
Intervention: MAP0010 low dose
Description: a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol

Intervention type: DRUG
Group type: OTHER
Intervention: MAP0010 low dose
Description: a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol

Intervention type: DRUG
Group type: OTHER
Intervention: MAP0010 high dose
Description: a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol

Intervention type: DRUG
Group type: OTHER
Intervention: MAP0010 high dose
Description: a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol

Intervention type: DRUG
Group type: OTHER
Intervention: Budesonide inhalation suspension 0.25mg
Description: a single dose of Pulmicort Respules® 0.25mg delivered by nebulization twice daily for 7 days as per protocol

Intervention type: DRUG
Group type: OTHER
Intervention: Budesonide inhalation suspension 0.25mg
Description: a single dose of Pulmicort Respules® 0.25mg delivered by nebulization twice daily for 7 days as per protocol

Intervention type: DRUG
Group type: OTHER
Intervention: Budesonide inhalation suspension 0.5mg
Description: a single dose of Pulmicort Respules® 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol

Intervention type: DRUG
Group type: OTHER
Intervention: Budesonide inhalation suspension 0.5mg
Description: a single dose of Pulmicort Respules® 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol
Study: NCT00862160

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ROCsafeTM
Description: using minimized perfusion circuit while CABG
Study: NCT00626431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate - Formulation A
Description: Leuprolide acetate was administered as 2 intramuscular (IM) injections of Formulation A, 45 mg 6 month depot, 24 weeks apart.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate - Formulation B
Description: Leuprolide acetate was administered as 2 intramuscular (IM) injections of Formulation B, 45 mg 6 month depot, 24 weeks apart.
Study: NCT02566954

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D measurement of the lower limb by EOS
Description: The intervention is to performed an additional radiologic exam by the EOS® system of imaging. This imaging is not usually realized for the patient.~3 dimensional study of lower limbs and feet of children in standing position will be performed using the EOS® system (EOS® Imaging, France)
Study: NCT04208841

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person-Centered Care Quality Improvement Collaborative Sustain
Description: Sustain improvements during QI collaborative focused on PCC

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person-Centered Care Quality Improvement Collaborative Sustain
Description: Sustain improvements during QI collaborative focused on PCC

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person-Centered Care Quality Improvement Collaborative Spread
Description: Implement change package developed during QI Collaborative

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person-Centered Care Quality Improvement Collaborative Spread
Description: Implement change package developed during QI Collaborative
Study: NCT00398008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/Subutex
Description: Opioid agonist medication to treat opiate dependence

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Opioid antagonist medication to treat opiate dependence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drug counseling
Description: DC-HIV: Drug Counseling that provides education about HIV, drug abuse and dependence; encourages medication adherence; uses motivational enhancement techniques; encourages life style changes; and teaches cognitive and behavioral coping skills to prevent relapse

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drug counseling
Description: DC-HIV: Drug Counseling that provides education about HIV, drug abuse and dependence; encourages medication adherence; uses motivational enhancement techniques; encourages life style changes; and teaches cognitive and behavioral coping skills to prevent relapse
Study: NCT04210206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PHE-diet
Description: phenylalanine-restricted diet with phenylalanine free supplements for 8 weeks
Study: NCT02373800

Intervention type: DEVICE
Intervention: Cervical ultrasound with elastography
Description: Following routine vaginal exam with determination of Bishop's score, cervical ultrasound with elastography will be used to determine a cervical hardness score varying from 1 to 10. Patients are then hospitalized and labor induced 12 to 48 hours after the elastography.
Study: NCT01881126

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bimatoprost 0.01%
Description: Bimatoprost 0.01% administered to both eyes once daily for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: travatan 0.004%
Description: Travatan 0.004% administered to both eyes once daily for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: timolol 0.5%
Description: Timolol 0.5% administered to both eyes once daily for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hypromellose 0.3%
Description: Hypromellose 0.3% lubricant eye drops (for masking purposes) administered to both eyes once daily for 12 weeks.
Study: NCT04598724

Intervention type: OTHER
Intervention: Surveys
Description: Survey will be administered involving questions regarding knowledge and perception of palliative care.

Intervention type: OTHER
Intervention: Surveys
Description: Survey will be administered involving questions regarding knowledge and perception of palliative care.
Study: NCT02057900

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human embryonic stem cell-derived CD15+ Isl-1+ progenitors
Description: Epicardial delivery of a fibrin patch embedding human embryonic stem cell-derived CD15+ Isl-1+ progenitors
Study: NCT01410773

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ninja 2 Investigational Blood Glucose Monitoring System
Description: The Ninja 2 meter is a Bayer investigational meter that uses an investigational sensor.